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Introduction: Neurofibromatosis type 1 is a common heritable neurocutaneous disorder. Neurofibromatosis type 1
may be associated with tumors of the central nervous system and pheochromocytoma. However, papillary thyroid
carcinoma associated with neurofibromatosis type 1 is very rare. We present what is, to the best of our knowledge,
the first case of papillary thyroid carcinoma to be detected incidentally by ultrasonography in a patient with
neurofibromatosis type 1.
Case presentation: A 63-year-old South Korean man with neurofibromatosis type 1 presented to our study
hospital because of thyroid nodules detected incidentally by ultrasonography. Papillary thyroid carcinoma was
diagnosed by ultrasonography-guided fine-needle aspiration, and then a total thyroidectomy with central
compartment neck dissection was performed. The B isoform of the RafV600E mutation was identified by multiplex
real-time polymerase chain reaction assay.
Conclusions: Papillary thyroid carcinoma associated with neurofibromatosis type 1 is very rare. However, it is
speculated that papillary thyroid carcinoma is more likely to be detected in patients with neurofibromatosis
type 1 if screening by ultrasonography is performed for them.Introduction
Neurofibromatosis type 1 (NF1) is an autosomal domin-
ant neurocutaneous disorder in which tumors involving
the sheaths or peripheral nerves are associated with
café-au-lait spots. NF1 is caused by mutation of the
NF1 gene on chromosome 17q11.2 [1]. The NF1 gene
encodes for neurofibromin, which acts as a tumor-
suppressor protein. NF1 may be associated with other
tumors of the central nervous system, including optic
glioma, glioblastoma, and meningioma, and rarely with
pheochromocytoma. However, papillary thyroid carcin-
oma (PTC) associated with NF1 is very rare, and only
three cases – all of which involved large tumors – have
been reported in the literature [2-4]. Recently, the PTC
of a patient with NF1 was diagnosed incidentally by
thyroid ultrasonography (US). To the best of our* Correspondence: yschoi@kosinmed.or.kr
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reproduction in any medium, provided the orknowledge, it is the first case of PTC to be detected inci-
dentally by US in a patient with NF1.
Case presentation
A 63-year-old South Korean man with NF1 presented at
our endocrine center because of thyroid nodules that
were found incidentally by US at a general health
checkup. His family history was unremarkable. A phys-
ical examination revealed neurofibromas covering the
entire surface of his body, café-au-lait macules on his
calf, and skin fold freckling (Figure 1); there were no
Lisch nodules on his iris, and his thyroid was unremark-
able. The results of a complete blood count, serum
biochemistry, and urine analysis were normal. Our
patient was euthyroid and had serum levels of free
Thyroxine (T4) at 0.83ng/dL (normal range was 0.78
to 1.54ng/dL), thyroid-stimulating hormone levels of
3.495μIU/mL (normal range was 0.55 to 4.78μIU/mL),
and thyroglobulin of 43.05ng/mL (normal range was
1.4 to 78.0ng/mL). Autoimmune antibodies such as anti-
thyroglobulin and anti-microsomal antibodies were
within the normal limits.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 (a,b) Neurofibromas covering the entire surface of the patient’s body. (c) Café-au-lait macules on the calf. (d) Skin fold freckling.
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homogeneous nodule with clear margins in the right
lobe (Figure 2a) and a 1.25 × 1.38cm markedly hypoe-
choic, microcalcified, extracapsular extension nodule
with irregular margins in the mid-portion of the left lobe
(Figure 2b). A US-guided fine-needle aspiration biopsy
(FNAB) was performed on the thyroid nodule. FNA
cytology diagnosed suspicious PTC. Magnetic resonance
imaging of the brain did not indicate hydrocephalus.
Our patient underwent a total thyroidectomy with a
central compartment neck dissection for the thyroidFigure 2 Transverse ultrasonography images of thyroid nodules. (a) In
nodule with a halo was observed. (b) In the left lobe, a markedly hypoecho
and extracapsullar extension was observed in the middle portion.tumor. Metastasis of seven central lymph nodes at left
level VI was confirmed. The tumor in the left thyroid
gland was gray-white and abutted the thyroid capsule.
Microscopically, the left thyroid tumor mass was dense
and contained pink-staining colloid, clear overlapping
nuclei, and nuclear grooves. The left thyroid tumor was
diagnosed as PTC. The nodule in the right thyroid gland
was microscopically diagnosed as nodular hyperplasia.
A solid skin tumor was visible as a gray-white round
mass. The outer surface was surrounded by a thin cap-
sule, and the cut surface was homogenously gray-white.the right lobe, a 0.79 × 0.75cm hypoechoic and homogeneous
ic 1.25 × 1.38cm nodule with irregular margins, microcalcification,
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consisted of spindle-shaped cells with wavy and tapered
nuclei. The cells showed positive staining for S-100, and
a neurofibroma was diagnosed.
B isoform of the Raf (BRAF)V600E mutation was identi-
fied by multiplex real-time polymerase chain reaction
(PCR) assay by using Anyplex™ BRAF V600E Real-time
Detection (version 2.0; Seegene, Seoul, South Korea),
which allows simultaneous amplification of total nucleic
acid of V600E mutation of BRAF and internal control
(human beta globin gene) (Figure 3). Genomic deoxy-
ribonucleic acid (DNA) was isolated from the formalin-
fixed paraffin-embedded (FFPE) surgical tissue resections
by using a QIAampW DNA FFPE tissue kit (Qiagen,
Hilden, Germany), and real-time PCR was performed
with the CFX96™ Real-Time PCR system (Bio-Rad
Laboratories, Inc., Hercules, CA, USA).
At present, our patient is following up as an out-
patient. Radioactive iodine treatment is planned for
adjuvant therapy of the papillary carcinoma.
Discussion
NF1, also known as von Recklinghausen disease, is an
autosomal dominant multisystem disorder that affects
approximately 1 in 3500 people [5]. In 1987, seven car-
dinal diagnostic criteria for NF1 were established [6].
If any two of the following seven criteria are met, a diag-
nosis of NF1 is made: (a) two or more neurofibromas
on or under the skin or one plexiform neurofibroma,
(b) freckling of the groin or the axilla (arm pit), (c) six
or more café-au-lait spots measuring 5mm in the great-
est diameter in prepubescent individuals and over 15mm
in the greatest diameter in post-pubescent individuals,
(d) skeletal abnormalities such as sphenoid dysplasia or
thinning of the cortex of the long bones of the body, (e)
two or more Lisch nodules (hamartomas of the iris), (f )
optic glioma, or (g) a first-degree relative with NF1.
These diagnostic criteria are highly specific to adults
with NF1. The patient in this study presented with
neurofibromas all over the surface of his body, multipleFigure 3 Detection of V600E mutation by using Anyplex™ BRAF V600
amplification of total nucleic acid of V600E and internal control (human becafé-au-lait spots, and axillary freckling. The NF1 gene
was discovered in 1990. Mutational analysis is now
available in a clinical setting and is useful for diagnostic
confirmation of individuals who do not fulfill diagnostic
criteria or when a prenatal diagnosis is desired [7].
Neurofibromatosis is an autosomal dominant disorder,
meaning that only one copy of the affected gene is
needed for the disorder to develop. Therefore, if only
one parent has neurofibromatosis, his or her children
have a 50% chance of developing the condition as
well. The severity in affected individuals can vary and
this variation may be due to variable expressivity. An
individual with mild clinical symptoms can have a more
severe phenotype and so genetic counseling is important
[7]. Approximately half of the known cases are due to
de novo mutations and no other affected family mem-
bers are seen. The patient in this case had no family his-
tory of NF1, suggesting that he has a de novo mutation.
PTC is one of the most common types of endocrine
cancer. The prevalence of thyroid cancer is rapidly in-
creasing in South Korea, and most cases are PTC. The
high rates of incidence of RET/PTC rearrangements or
point mutations in RAS and c-MET oncogenes are gen-
etic hallmarks of PTC [3]. The BRAF kinase is a serine-
threonine kinase that mediates signal transduction
through the MEK-ERK pathway. An activating mutation
of the BRAF kinase gene, located on exon 15, was
recently found to result in a valine-to-glutamic acid sub-
stitution at amino acid 600 (BRAFV600E mutation) that is
an oncogene in human cancer and the most common
mutation in PTC [8]. In recent years, the BRAFV600E
mutation has shown a high specificity for PTC, and its
prevalence is highly variable, ranging from 30% to more
than 80%, depending on the study. In the present study,
the BRAFV600E mutation was identified by multiplex
real-time PCR. This method is as sensitive as dual-
priming oligonucleotide-based multiplex PCR (Seegene)
for detecting BRAFV600E mutations.
The NF1 gene located on chromosome 17q11.2 encodes
neurofibromin. The Ras-GAP is a potentially functionalE Real-time Detection (Seegene). This product allows simultaneous
ta globin gene).
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domain (Ras-GRD) accelerates the conversion of active
Ras-GTP to inactive Ras-GDP in various cell types and
acts as a negative regulator of the p21ras signaling path-
way [10]. Ras GTPases interact with multiple pathways,
including the RAF-MEK-ERK mitogen-activated protein
kinase pathway. Mutations in the NF1 gene result in ab-
normal cell growth and in the formation of benign and
malignant tumors [3]. Because BRAFV600E mutation and
NF1 gene mutation are both involved in the MEK-ERK
pathway, Koksal et al. [3] suggested that the develop-
ment of PTC in patients with NF1 may be associated
with the ras gene but that further evidence is necessary
to confirm this association.
PTCs are very rare in NF1. Only three cases have been
reported. Nakamura et al. [4] reported a case of NF1
associated with a pheochromocytoma and PTC in a 58-
year-old woman. Hashiba et al. [2] reported a case of
skull metastasis from PTC in a 74-year-old woman with
NF1. Koksal et al. [3] reported neurofibroma adjacent to
the thyroid gland and PTC in a patient with NF1. These
cases all involved large tumors. The nodule in this study
was small and was incidentally diagnosed by thyroid US.
US features of malignant nodules include the presence
of microcalcifications, hypoechogenicity, and irregular
margins and the absence of a halo, predominantly solid
composition, and intra-nodular vascularity [11]. The
nodule in this case had irregular margins, hypoechogeni-
city, microcalcifications, and extracapsular extension on
US. This nodule was suspected to be associated with
PTC, and a US-guided FNAB was performed at the
thyroid nodule. The diagnosis based on FNA cytology
indicated suspicious PTC. A total thyroidectomy with
central compartment neck dissection of the thyroid
tumor was performed. The tumor in the left thyroid lobe
was diagnosed as PTC, and metastasis of seven central
lymph nodes at left level VI was confirmed.Conclusions
NF1 is a common heritable neurocutaneous disorder.
However, PTC associated with NF1 is very rare and only
three cases have been reported. To the best of our
knowledge, this is the first case of PTC to be detected
incidentally by US in a patient with NF1. It is speculated
that PTC is more likely to be detected in patients with
NF1 if screening by ultrasound is performed.Consent
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